Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy

American Journal of Tropical Medicine and Hygiene

Volumn 70, Issue 3, 2004, Pages 298-301

  Mira, Jose A ^a   Corzo, Juan E ^a   Rivero, Antonio ^b   Macias, Juan ^a   De Leon, Fernando Lozano ^a   Torre Cisneros, Julian ^b   Gomez Mateos, Jesus ^a   Jurado, Rafael ^b   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; MEGLUMINE ANTIMONATE; PENTAMIDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; FREQUENCY MODULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; VIRUS LOAD; VIRUS REPLICATION; VISCERAL LEISHMANIASIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTOZOA; RNA VIRUSES;

EID: 1642286036     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.70.298     Document Type: Article

References (15)

1. Pineda JA, Galardo JA, Macías J, Delgado J, Regordán C, Morillas F, Relimpio F, Martín-Sánchez J, Sánchez-Quijano A, Leal M, Lissen E. 1998. Prevalence of and factors asssociated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in soputhern Spain. J Clin Microbiol 36: 2419-2422.
2. Alvar J, Cañavete C, Gutiérrez-Solar B, Jiménez M, Laguna F, López-Vélez R, Molina R, Moreno F. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10: 298-319.
3. Gradoni L, Scalone A, Grammicia M, Troiani M. 1996. Epidemiological surveillance of leishmaniasis in HIV-1 infected individuals in Italy. AIDS 10: 785-791.
4. Delgado J, Pineda JA, Gallardo JA, Leal M, Macías J, Sánchez-Quijano A, Lissen E. 1998. Influencia de la actuación médica sobre la formu de presenlación del sida definido por episodios clínicos. Med Clin (Barc) 110: 125-127.
5. Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torre E, Medrano FJ, Sanz J, Pico G, Gómez-Rodrigo J, Pasquau J, Alvar J. 1999. Treatment of visccral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 13: 1063-1069.
6. Patella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sallen GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853-860.
7. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30: S5-S14.
8. de la Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, Sánchez-Quijano A, Leal M, Lissen E. 2002. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 40: 762-767.
9. Berenguer J, Cosín J, Miralles P, López J, Padilla B. 2000. Discontinuation of anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14: 2946 2948.
10. de la Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Martín-Sánchez J, Leal M, Sánchez-Quijano A, Lissen E. 2001. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 32: 633-635.
11. Casado JL, López-Vélez R, Pintado V, Quereda C, Antela A, Moreno S. 2001. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 20: 202-205.
12. Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J. 2000. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of the highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 19: 798-801.
13. Tortajada C, Pércz-Cuevas B, Moreno A, Martínez E, Mallolas J, García F, Valls E, Miró JM, De Lazzari E, Gutell JM. 2002. Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients (letler). J Aquir Immune Defic Syndr 30: 364-366.
14. Pineda JA, Macías J, Morillas F, Fernández-Ochoa J, Cara J, de la Rosa R, Mira JA, Martín-Sánchez J, González M, Delgado J, Acedo C, Lissen E. 2001. Evidence of increased risk for Leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain. Eur J Clin Microbiol Infect Dis 20: 354-357.
15. Morales MA, Cruz I, Rubio JM, Chicharro C, Canavete C, Laguna I, Alvar J. 2002. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J Infect Dis 185: 1533-1537.